Saxenda vs Wegovy
Saxenda vs Wegovy represents the evolution of GLP-1 weight loss medications. Both contain GLP-1 agonists, but Wegovy's weekly dosing and superior efficacy have made Saxenda largely obsolete for most patients.
First Generation vs Next Generation
Saxenda was the first GLP-1 medication approved specifically for weight loss (2014). Wegovy arrived seven years later with significant improvements. Here's how they compare:
| Feature | Saxenda | Wegovy |
|---|---|---|
| Active Ingredient | Liraglutide | Semaglutide |
| Drug Class | GLP-1 agonist | GLP-1 agonist |
| Dosing Frequency | Daily injection | Weekly injection |
| FDA Approval | December 2014 | June 2021 |
| Avg Weight Loss | 8-12% | 15-17% |
| Cardiovascular Benefit | No specific indication | Approved CV indication |
| Manufacturer | Novo Nordisk | Novo Nordisk |
The Efficacy Gap
Weight Loss Comparison
The difference in average weight loss is substantial:
- Saxenda (SCALE trial): 8.0% body weight loss over 56 weeks
- Wegovy (STEP-1 trial): 14.9% body weight loss over 68 weeks
For a 250-pound person:
- Saxenda: ~20 pounds average loss
- Wegovy: ~37 pounds average loss
And Wegovy's longer duration means the gap widens further over time.
Patients Achieving Significant Weight Loss
| Milestone | Saxenda | Wegovy |
|---|---|---|
| Lost ≥5% body weight | 63.2% | 86.4% |
| Lost ≥10% body weight | 33.1% | 69.1% |
| Lost ≥15% body weight | 15.4% | 50.5% |
Dosing Convenience
The difference in dosing frequency is perhaps the biggest practical advantage:
Saxenda: Daily Commitment
- One injection every day
- Can be taken any time of day
- Must remember to carry pen when traveling
- More injection site reactions from frequent injections
Wegovy: Weekly Freedom
- One injection per week
- Same day each week
- Only 52 injections per year vs 365
- Less injection fatigue
Side Effect Comparison
Both drugs cause similar GI side effects, but patterns differ:
| Side Effect | Saxenda | Wegovy |
|---|---|---|
| Nausea | 39% | 44% |
| Diarrhea | 21% | 30% |
| Constipation | 19% | 24% |
| Vomiting | 15% | 24% |
| Discontinuation Rate | ~10% | ~7% |
Despite higher efficacy, Wegovy has slightly lower discontinuation rates, likely due to weekly dosing convenience.
Pediatric Use
Saxenda: Approved for Ages 12+
FDA-approved for chronic weight management in adolescents aged 12-17 with:
- Body weight above 60 kg (132 lbs)
- BMI ≥30 (or ≥95th percentile for age/sex if BMI <30)
Wegovy: Approved for Ages 12+
Also FDA-approved for adolescents, with similar criteria. The STEP TEENS trial showed:
- 72.5% of teens lost ≥5% body weight
- Mean weight loss: 14.7%
Both are options for adolescents, though Wegovy's weekly dosing is preferable for compliance.
Cost Considerations
List Prices (2024)
- Saxenda: ~$1,349/month
- Wegovy: ~$1,349/month
Similar pricing despite Wegovy's superior efficacy.
Savings Programs
Both Novo Nordisk medications have savings cards:
- Saxenda: Up to $200/month off for eligible commercial insurance
- Wegovy: Up to $225/month off for eligible commercial insurance
- Both offer $25/month for patients without coverage (while supplies last)
Why Is Saxenda Still Prescribed?
Despite being inferior, Saxenda persists in prescribing for several reasons:
Insurance Coverage
Some insurance plans haven't updated formularies and still cover Saxenda but not Wegovy. This is increasingly rare.
Patient Preference
A small minority prefer daily injections for perceived control, or they successfully lost weight on Saxenda and don't want to switch.
Supply Issues
During Wegovy shortages (2022-2023), Saxenda was sometimes the only available option.
Insurance Step Therapy
Some plans require trying Saxenda first before approving Wegovy (prior authorization "fail first" policies).
Switching from Saxenda to Wegovy
Most patients on Saxenda should consider switching to Wegovy:
Transition Process
- Stop Saxenda (can stop immediately)
- Start Wegovy at 0.25mg weekly (starting dose regardless of Saxenda dose)
- Follow standard titration schedule
- New insurance authorization required
Expected Results
Patients switching often report:
- Better appetite suppression
- More weight loss
- Appreciation for weekly vs daily injections
- Similar or better side effect profile
When Saxenda Might Make Sense
There are limited scenarios where Saxenda remains viable:
- Insurance only covers Saxenda
- Patient strongly prefers daily dosing
- Already achieving good results and satisfied
- Wegovy not available in patient's region
For most patients, Wegovy represents a clear upgrade.